Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
| Autor: | Sonia Molina-Pinelo, Reyes Bernabé-Caro, Amparo Sanchez-Gastaldo, Miriam Alonso-García, Laura Boyero, Miguel A. Muñoz-Fuentes |
|---|---|
| Přispěvatelé: | Fundación Mutua Madrileña, Junta de Andalucía, Instituto de Salud Carlos III, European Commission, Universidad de Sevilla. Departamento de Medicina, Ministerio de Salud y Bienestar Social de la junta de Andalucia |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Proportional hazards model business.industry Hazard ratio non-small cell lung cancer (NSCLC) Non-small cell lung cancer (NSCLC) medicine.disease Gastroenterology Confidence interval Blood biomarkers medicine.anatomical_structure Oncology White blood cell Internal medicine medicine Biomarker (medicine) Original Article Progression-free survival Lung cancer business Pembrolizumab |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname Transl Lung Cancer Res |
| ISSN: | 0046-2012 |
| Popis: | [Background] Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes and three peripheral blood biomarkers, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR), as well as a new score termed the risk blood biomarker (RBB), calculated from the combination of the neutrophil-monocyte-to-lymphocyte ratio (NMLR) and white blood cell count (WBC). [Methods] This study included patients with stage IV or recurrent NSCLC confirmed with programmed death ligand 1 (PD-L1) expression ≥50% who received pembrolizumab monotherapy as first-line treatment at the Virgen del Rocío University Hospital in Seville, Spain. To establish the relationship between baseline peripheral blood biomarkers and survival outcomes, progression free survival (PFS) and overall survival (OS), we used the Kaplan-Meier method and multivariable Cox regression models. [Results] A total of 51 patients were included in this study. In multivariate analysis, baseline NLR and PLR showed a strong association with PFS [NLR hazard ratio (HR): 0.19, 95% confidence interval (CI): 0.09–0.44, P [Conclusions] Low baseline NLR, MLR and PLR are significantly associated with better PFS, and low baseline NLR and PLR are associated with better OS. Additionally, we identified three subgroups of patients using the RBB score, and low scores were associated with improved survival outcomes and response to therapy. SMP was funded by the Fundación Mutua Madrileña (2014), Ministry of Health and Social Welfare of Junta de Andalucía (PI-0046-2012, Nicolas Monardes Program RC-0004-2020 and OH-0022-2018), ISCIII (PI17/00033 and PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union). LB was funded by the Ministry of Health and Social Welfare of Junta de Andalucía (RH-0051-2020). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|